Galmed to employ onkai's disruptive artificial intelligence (ai) in its planned phase 2a clinical trial in psc

Onkai's ai models redefine the methodologies and economics of clinical trials tel aviv, israel , july 10, 2023 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, is delighted to announce the first step in its strategic partnership with onkai, where onkai will apply its artificial intelligence (ai), models for enrollment and execution of clinical trials in underserved communities, starting with galmed's innovative primary sclerosing cholangitis (psc) clinical development program.
GLMD Ratings Summary
GLMD Quant Ranking